Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM230 LAR + Bortezomib + Dexamethasone in RRMM
NCT01329289Phase 2Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Dec 2011
- Primary completion
- Feb 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in multiple myeloma (MM), sponsored by University of Pittsburgh. Primary endpoint: Objective Tumor Response at 2 years. Planned start Dec 2011; status: withdrawn.
02
Drugs
pasireotide LAR
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01329289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01329289.